10.04.2021 · At AACR, preclinical data highlighted a set of potent and selective CDK2 inhibitors designed by Blueprint Medicines. The data showed that selective CDK2 inhibition arrested the cell cycle and blocked tumor proliferation in CCNE-amplified cell lines and demonstrated robust and sustained anti-tumor activity in vivo in models of CCNE-amplified ovarian, breast and gastric …
28.07.2021 · HOUSTON and CAMBRIDGE, Mass., July 28, 2021 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation (NASDAQ: BPMC) today announced a three-year strategic research collaboration focused on accelerating development of BLU-222, an investigational precision therapy designed to target cyclin-dependent kinase 2 …
28.07.2021 · MD Anderson and Blueprint Medicines announce strategic collaboration to accelerate BLU-222 development. Translational research will focus on advancing therapeutic strategies for Blueprint Medicines’ potent and selective CDK2 inhibitor across a broad range of tumor types. MD Anderson News Release July 28, 2021
CDK2 essential 0 –2 –4 ... Knutsford, UK, supported by Blueprint Medicines Corporation, Cambridge, MA, according to Good Publication Practice guidelines. Disclosures This research was funded by Blueprint Medicines Corporation. Blueprint Medicines Corporation reviewed and provided feedback on the poster.
28.07.2021 · Blueprint and MD Anderson intend to home in on certain cancers that are most susceptible to CDK2 inhibition and identify biomarkers that predict which patients will respond to BLU-222. Already, Blueprint plans to begin a Phase I clinical trial next year of BLU-222 in patients with cancers that have aberrant cyclin E, or CCNE, a tumor growth driver associated with …
Blueprint Medicines, AYVAKIT™, AYVAKYT®, GAVRETO™ and associated logos are trademarks of ... CDK2, a cyclin-dependent kinase involved in cell cycle biology, ...